SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently trending as investors debate whether the recent price decline represents an oversold opportunity or a long-term exhaustion of the project's potential. While some community members are actively dollar-cost averaging to lower their cost basis, others are voicing frustration over the persistent disconnect between the network's ongoing enterprise utility and the token's stagnant market performance.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is attracting significant market attention following a robust Q1 earnings report, continued volume growth for its key products, and ongoing speculation regarding potential strategic acquisitions by Zydus Lifesciences. Investors are closely monitoring the stock as it gains momentum, balancing positive commercial execution with the anticipation of a definitive court ruling regarding the company's long-standing Medicare reimbursement dispute.

BTQ Technologies Corp. engages in the business of post-quantum encryption. Its products include: QCIM, QSSN, OSS, QPoW, QRiNG. The company was founded by Nicolas Roussy Newton on Novemeber 23, 1983 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ is gaining significant community traction as investors track its post-quantum cybersecurity developments, including a new hardware hub in New York and strategic engineering hires aimed at accelerating commercialization. While some are debating the volatility of its retail-heavy trading patterns and the impact of internal management drama, the consensus focus remains on the urgent industry need for quantum-resistant infrastructure and the potential for long-term growth through future commercial partnerships.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending as the community debates the commercial launch of NEREUS for motion sickness and speculates on potential acquisition interest from major pharmaceutical players. Investors remain focused on the company's GLP-1 adjunct pipeline and upcoming clinical study results, even as sentiment is tempered by frustration over price volatility and management's aggressive regulatory strategy.

Sezzle, Inc. engages in the operation of a digital payment platform that enables bank-to-bank transfer of money between consumers and businesses. The company was founded by Charlie G. Youakim, Killian Brackey and Paul V. Paradis on January 4, 2016 and is headquartered in Minneapolis, MN.

Sezzle Inc.

Sezzle is seeing intense community debate as investors weigh the stock's long-term fintech fundamentals against recent volatility and aggressive short-selling activity. While some traders are focused on potential short squeezes and high-growth metrics, others are closely monitoring board governance changes and broader market macro-headwinds.

Sui s a Layer 1 blockchain developed by Mysten Labs, a team founded by former lead engineers from Meta’s blockchain research division. It is designed for global adoption by providing a secure, high-speed environment for digital asset ownership and removing technical barriers for Web3 applications. The platform utilizes the Move programming language to create a safe framework and supports horizontal scaling to keep fees stable and speeds high as the network grows. Significant institutional support comes from major venture capital firms including Andreessen Horowitz, Coinbase Ventures, Circle Ventures, and YZi Labs.  The system functions by organizing data into independent objects rather than a single ledger of accounts. This object-centric data model enables parallel execution, allowing the network to process many transactions simultaneously instead of waiting for one to finish before starting the next. This architecture is built for rapid transaction finalization to ensure near-instant results. To maintain long-term stability, the network collects fees into a storage fund that rewards validators for keeping data on the network indefinitely.  Sui offers several advanced tools including zkLogin for easier account access and sponsored transactions that allow users to interact with apps without managing complex wallets or immediate fees. Developers can also create tailored object types that work across the entire network, which encourages innovation and deep composability. These features are designed to create a more user-friendly experience for interacting with decentralized applications and digital games.  The SUI token is central to the ecosystem, serving as the primary asset for transaction fees and on-chain utility within decentralized exchanges and lending platforms. Users participate in a proof-of-stake mechanism by locking their tokens to support validators and secure the blockchain in exchange for rewards. Additionally, token holders have a role in governance, allowing them to participate in voting on network rules and future protocol upgrades. Value moves through the system through these staking rewards and transaction fees to ensure the platform scales sustainably

SUI is experiencing significant market volatility characterized by intense selling pressure and network stability concerns, leading to polarized community sentiment between those calling for a bottom and those warning of further downside. Traders are actively debating whether to accumulate during the current dip or remain on the sidelines until the protocol shows sustained recovery.

Flutter Entertainment Plc engages in the business of online betting and gaming. It operates through the following segments: UK and Ireland, Australia, International, and US. The UK and Ireland segment includes the operations of Sky Betting and Gaming, Paddy Power, Betfair, and tombola. The Australia segment focuses on sports betting services provided to Australian customers online. The International segment relates to poker, casino, rummy, lottery, and sports betting. The US segment includes sports betting, daily fantasy sports, and gaming services. The company was founded in 1988 and is headquartered in New York, NY.

Flutter Entertainment Plc

Flutter Entertainment is currently under significant market pressure following a series of negative analyst outlooks and leadership changes at its FanDuel division, which have compounded ongoing investor concerns regarding U.S. betting growth and intensifying competition. Despite these headwinds, the community is actively debating the company's valuation as a potential long-term value play, focusing heavily on how it will navigate regulatory uncertainty and the rise of prediction market platforms.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors react to overwhelmingly positive Phase 3 clinical data for retatrutide, which demonstrates significant weight loss and health benefits, while broader community interest remains focused on the company's ability to maintain its market-leading position through aggressive pipeline expansion and diversified R&D strategies. The community is actively debating the stock's valuation as it nears new all-time highs, with discussions frequently comparing Lilly's growth potential against its main competitor, Novo Nordisk.

Aurora Innovation, Inc. engages in the design and development of automobile hardware, software, and provision of data services. It offers the Aurora Driver which allows a vehicle to drive itself. The company was founded by Christopher Urmson, Sterling Anderson and James Andrew Bagnell in 2017 and is headquartered in Pittsburgh, PA.

Aurora Innovation Inc - Ordinary Shares - Class A

Aurora Innovation is surging as investors react to positive autonomous trucking developments, including expanded logistics partnerships and increased analyst attention. The community is actively discussing a potential short squeeze driven by significant institutional ownership and anticipation of major milestones as the company scales its driverless technology.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Lingo, magicJack, Marconi Wireless, United Online (UOL), and Consumer Products. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Lingo segment offers a global cloud or unified communications and managed service provider to Enterprise and Small to Medium Businesses in the United States. The magicJack VoIP segment is a non-interconnected Voice-over-IP (VoIP) cloud-based communications service provider that offers related devices and subscription services within the United States and Canada. The Marcon segment is a mobile virtual network operator that provides mobile phone voice, text, and data services and devices using the Credo Mobile brand. The United Online segment is an Internet access provider that offers dial-up and digital subscriber line services under the NetZero and Juno brands across the United States. The Consumer Products segment generates revenue through sales of laptop and computer accessories. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is currently trending as investors monitor its significant investment portfolio, including its SpaceX exposure and Babcock & Wilcox, alongside anticipation for the upcoming Russell Index inclusion. Community discussion centers on potential valuation catalysts, the firm's ongoing debt management strategies, and the impact of these high-profile holdings on its long-term turnaround narrative.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CADL Stock Heads For Best Week In A Month – Here’s Why Retail Is Bullish

Equity

Candel Therapeutics Phase 3 prostate cancer trial showed a higher disease-free survival rate.

Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade

The mean of analysts' price targets for Candel Therapeutics (CADL) points to a 148.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data

Candel Therapeutics presented positive phase 3 prostate cancer data showing improved disease-free survival, while analysts maintained bullish expectations on the stock.read more...

CADL Stock Edges Up After Hours On Strong Extended Prostate Cancer Data  

The company reported that, after a median follow-up of 58 months, CAN-2409 delivered a statistically significant 39% improvement in prostate cancer-specific disease-free survival versus placebo. 

CADL Retail Bulls See Buyout Potential As Key Cancer Data Catalyst Approaches

Candel Therapeutics is set to present data on Friday from its Phase 3 clinical trial of Aglatimagene in patients with localized, intermediate- to high-risk prostate cancer

Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow 

Candel Therapeutics generated investor buzz ahead of a key prostate cancer data readout, while its first-quarter loss came narrower than consensus estimates.

Candel Therapeutics (NASDAQ:CADL) Sets New 12-Month High  - Here's What Happened

Candel Therapeutics (NASDAQ:CADL) Hits New 52-Week High - What's Next...

Candel Therapeutics (CADL) to Release Earnings on Tuesday

Candel Therapeutics (NASDAQ:CADL) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-candel-therapeutics-inc-stock...

Candel Therapeutics (NASDAQ:CADL) Stock Price Up 6.1% - Should You Buy?

Candel Therapeutics (NASDAQ:CADL) Trading 6.1% Higher - Here's Why...

UCB To Acquire Candid Therapeutics For Up To $2.2 Bln To Boost Immunology Pipeline

(RTTNews) - United Community Banks, Inc. (UCB),on Sunday agreed to buy Candel Therapeutics, Inc. (CADL) for up to $2.2 billion, aiming to strengthen its pipeline of treatments for immune-related diseases...

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

CADLCandel Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CADL News